ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 512

Memory B Cell Phenotypic and Gene Expression Profiling in Primary Sjogren’s Syndrome: Implications for Disease Diagnosis

Mustimbo E. P. Roberts1, Craig Maguire1, Alex Rosenberg2, Andreea Coca3, Jennifer H. Anolik4 and Inaki Sanz5, 1University of Rochester School of Medicine and Dentistry, Rochester, NY, 2University of Rochester, Rochester, NY, 3Univ of Rochester, Rochester, NY, 4Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 5Medicine/Rheumatology, Rochester, Rochester, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: B cells and Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Title: Sjögren's Syndrome - Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: A paucity of known causative mechanisms in primary Sjögren’s Syndrome (pSS) contributes to inadequate classification criteria. However, known memory-phenotype B cell aberrations could enrich diagnostic criteria if such alterations precede clinical disease onset. Therefore, to determine diagnostic potential, we compared the phenotype and gene expression of B cells in pSS patients, sicca patients (individuals with symptoms but without pSS diagnosis), and healthy controls (HCs). 

Methods:

CD19pos B cells from pSS (n=26), from sicca symptomatic patients (n=27), and from healthy controls (n=22) were analyzed using flow cytometry to identify canonical B cell subsets.  Sub-groups of these subjects were further analyzed for expression of CD21, CD23, CD24, CD95 CXCR5 and CD1c.  Additionally, purified B cell subsets (n=3-5, per group, per test) were analyzed for gene expression using Affymetrix gene arrays.

Results:

pSS patients had lower frequencies and numbers of CD27pos/IgDneg switched memory (SM) and CD27pos/IgDpos unswitched memory (UM) phenotype B cells compared with HCs. A sub-group of sicca patients shared a B cell profile similar to pSS.  Interestingly, lower UM B cell frequencies were evident in sicca patients before disease-associated autoantibodies were detectable. Importantly, patient UM B cell frequency significantly associated with serologic hyperactivity.  Extended phenotypic profiling in pSS revealed that the deficient UM cells had marginal zone B cell characteristics, whereas the SM cells were enriched for likely pathogenic effectors. CD27pos memory B cell gene-expression profiling identified 135 differentially expressed genes between pSS patients and HCs.  Additionally, clustering analysis identified a subgroup of sicca patients with a gene expression profile similar to pSS. Whereas SM B cells gene expression analysis was similar in pSS and HCs, UM B cell gene expression analysis identified 187 differentially expressed genes between pSS patients and HCs. Interestingly, some of the these genes encoded signaling molecules and transcriptional factors associated with many B cell related biological pathways.

Conclusion:

Collectively, these findings suggest that UM B cells contribute to regulating autoimmunity and also that B cell profiling could enhance diagnosis of pSS onset.  Thus, B cell profiling in pSS has the potential to identify early disease-onset candidates for earlier therapeutic intervention and for novel therapies under investigation.


Disclosure:

M. E. P. Roberts,
None;

C. Maguire,
None;

A. Rosenberg,
None;

A. Coca,
None;

J. H. Anolik,
None;

I. Sanz,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/memory-b-cell-phenotypic-and-gene-expression-profiling-in-primary-sjogrens-syndrome-implications-for-disease-diagnosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology